<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110831">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01756365</url>
  </required_header>
  <id_info>
    <org_study_id>LOEX 015</org_study_id>
    <nct_id>NCT01756365</nct_id>
  </id_info>
  <brief_title>Autologous Cultured Corneal Epithelium (CECA) for the Treatment of Limbal Stem Cell Deficiency</brief_title>
  <acronym>CECA</acronym>
  <official_title>Autologous Cultured Corneal Epithelium ( Culture d'épithélium cornéen Autologue CECA) for the Treatment of Unilateral Corneal Lesions Associated With Limbal Stem Cell Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Québec, CHU de Québec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Québec, CHU de Québec</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study &quot; Autologous cultured corneal epithelium (CECA) for the treatment of unilateral
      corneal lesions associated with limbal stem cell deficiency&quot; is the first clinical trial of
      this product manufactured at the LOEX laboratory. The culture of corneal epithelium strives
      to produce a reconstructed tissue with the therapeutical aim of treatment of unilateral
      limbal stem cell deficiency (only one eye is affected by the limbal stem cell deficiency).
      The study is a phase I/phase II study with the goal to evaluate safety and efficacy of the
      CECA graft for the treatment of human patients suffering from limbal stem cell deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation according to the Snellen scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>epithelial deficit</measure>
    <time_frame>1 year</time_frame>
    <description>Slit lamp examination: coloration with Fluorescein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opacity / transparency of the cornea</measure>
    <time_frame>1 year</time_frame>
    <description>Slit lamp examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peripheral and central vascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Slit lamp examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integrity of the surface of the epithelium</measure>
    <time_frame>1 year</time_frame>
    <description>Slit lamp examination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Limbal Stem Cell Deficiency</condition>
  <arm_group>
    <arm_group_label>CECA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical transplantation of CECA</intervention_name>
    <arm_group_label>CECA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients with limbal stem cell deficiency

        Exclusion Criteria:

          -  Bilateral limbal stem cell deficiency

          -  Unilateral limbal stem cell deficiency with more than 50% of damage to the
             contralateral eye

          -  Pregnancy

          -  Breast-feeding

          -  Minors

          -  known allergy to aprotinine (Trasylol (R))

          -  Hypersensibility to bovine proteins
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre universitaire d'Ophtalmologie CHU de Québec - HSS</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>December 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Québec, CHU de Québec</investigator_affiliation>
    <investigator_full_name>Richard Bazin</investigator_full_name>
    <investigator_title>Clinical professor ophtalmology, director of the cornea service</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
